Detalhe da pesquisa
1.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
2.
Clinical and pathological features of clonal cytopenia of undetermined significance presenting with isolated thrombocytopenia (CCUS-IT).
Eur J Haematol
; 112(4): 594-600, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088145
3.
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Cancer
; 124(2): 325-334, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29211308
4.
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Lancet Oncol
; 18(10): 1317-1326, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844816
5.
Approach to the management of incidental venous thromboembolic events in patients with cancer.
J Natl Compr Canc Netw
; 12(11): 1557-60, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25361802
6.
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Blood Adv
; 8(8): 2020-2029, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231126
7.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Lancet Haematol
; 11(1): e15-e26, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135371
8.
Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support.
Blood Adv
; 7(13): 3058-3068, 2023 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476017
9.
Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning.
Leuk Res Rep
; 17: 100328, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35663282
10.
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Clin Cancer Res
; 28(7): 1313-1322, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35091444
11.
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
Clin Cancer Res
; 28(24): 5306-5316, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36222848
12.
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
J Clin Oncol
; 40(15): 1671-1680, 2022 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35180010
13.
Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans.
Blood Adv
; 3(21): 3278-3286, 2019 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31698456
14.
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera.
Hemasphere
; 6(6): e721, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35747843
15.
Treating venous thromboembolism in patients with cancer.
Expert Rev Hematol
; 5(2): 201-9, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22475288
16.
Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond.
Expert Rev Hematol
; 1(2): 175-82, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21082922
17.
Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance.
J Clin Oncol
; 24(30): 4928-32, 2006 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17050877